Clinical Trials

Multiple Myeloma, Recurrence

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

440 enrolled

Multiple Myeloma, Recurrence

NCT05652335 2026-03-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

180 enrolled

Amyloidosis, Multiple Myeloma, Recurrence

NCT06425991 2026-03-13

MajesTEC-10

108 enrolled

Multiple Myeloma, Recurrence

NCT06604715 2026-03-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

80 enrolled

Multiple Myeloma, Recurrence

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

30 enrolled

Multiple Myeloma, Recurrence

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

810 enrolled

Multiple Myeloma, Recurrence

NCT03361306 2026-03-06

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

15 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT06375044 2026-03-06

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

130 enrolled

Multiple Myeloma, Recurrence

NCT05927571 2026-03-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

120 enrolled

Multiple Myeloma, Recurrence

NCT07280013 2026-03-05

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

60 enrolled

Bites and Stings, Multiple Myeloma, Recurrence

NCT03601078 2026-03-04

KarMMa-2

Phase 2 Completed

312 enrolled

Multiple Myeloma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

228 enrolled

Multiple Myeloma, Recurrence

NCT07116616 2026-02-24

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

166 enrolled

Multiple Myeloma, Recurrence

NCT05530421 2026-02-23

SELVEDge

33 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05572515 2026-02-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

MyeloidOther hematologic neoplasmPlasma cell

21 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT03761108 2026-02-11

LINKER-MM1

387 enrolled 1 FDA

Multiple Myeloma, Recurrence

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05014412 2026-02-10

MagnetisMM-9

Phase 2 Completed

86 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT06297226 2026-02-10

QUINTESSENTIAL

230 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Multiple Myeloma, Recurrence

NCT07234721 2026-02-10

SL4903

9 enrolled

Multiple Myeloma, Recurrence

NCT03374085 2026-02-09

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 1/2 Terminated

200 enrolled

Multiple Myeloma, Recurrence

NCT07105059 2026-02-09

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

18 enrolled

Multiple Myeloma, Recurrence

NCT06215118 2026-02-05

MagnetisMM-30

87 enrolled

Multiple Myeloma, Recurrence

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

70 enrolled

Multiple Myeloma, Recurrence

NCT07369895 2026-01-27

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

18 enrolled

Multiple Myeloma, Recurrence

NCT05675449 2026-01-26

MagnetisMM-20

90 enrolled

Multiple Myeloma, Recurrence

NCT05714839 2026-01-23

DREAMM-20

153 enrolled

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05455320 2026-01-16

MonumenTAL-3

864 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT07348393 2026-01-16

Mezi-KD

70 enrolled

Multiple Myeloma, Recurrence

NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

33 enrolled

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

50 enrolled

Multiple Myeloma, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

90 enrolled

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

300 enrolled